India has approved its first dengue vaccine for people aged 4 to 60. The approval matters because dengue remains a recurring mosquito-borne public-health challenge, and a vaccine can complement vector control, surveillance, and clinical care.
India will deploy the vaccine through the immunization ecosystem after appropriate regulatory and rollout steps. The immediate policy question is not only scientific efficacy, but also how quickly the vaccine can move from approval to safe and equitable public access.
What changed now
India now has an approved dengue vaccine for the first time. Earlier, dengue control depended mainly on mosquito-control measures, early diagnosis, clinical management, and public-health campaigns.
Why it matters for UPSC
The approval connects public health, biomedical research, and immunization policy. It is relevant for questions on disease burden, prevention strategy, regulatory clearance, and the capacity of the health system to deliver new interventions.
Related current affairs
- CDSCO approves India’s first dengue vaccine (Qdenga)
- Expert Explains: Viruses and vaccines—what timely access means for outcomes (header-only/short module)
- ‘No new H1N1 strain in India, existing vaccines sufficient’
- Nadda reviews preparedness, calls for robust surveillance as H1N1 cases rise in Delhi
- Faith healing poses challenge to authorities as diseases kill 7 tribal children in Madhya Pradesh
- Dementia risks you can change